Despite being a major pharmaceutical manufacturer, India imports certain finished pharmaceutical formulations from Australia due to several factors:
1. Patented Drugs and Biologics: India's domestic industry primarily focuses on generic drugs, which are off-patent. However, patented drugs and biologics, often produced by Australian companies, are not manufactured locally due to patent protections and the complexity of biologic production.
2. Specialty Products and Technology Gaps: Certain specialized formulations, such as advanced cancer treatments and complex biologics, require sophisticated technology and expertise. Indian manufacturers may lack the necessary capabilities to produce these products, leading to reliance on imports from countries like Australia.
3. Regulatory Approvals and Market Access: Australian pharmaceutical companies often have established regulatory approvals and market access in India, facilitating smoother entry for their products. This established presence makes it easier for Indian consumers and healthcare providers to access these medications.
In 2022, India imported pharmaceutical products from Australia valued at $52.9 million USD, comprising 889 shipments from 140 foreign suppliers to 111 Indian buyers. The average shipment value was $60,000 USD. The top imported products included serums, cytarabine, carboplatin, and irinotecan, indicating a focus on specialized and high-value medications.
